Oral semaglutide cuts major heart risks in people with type 2 diabetes by 14%, offering a powerful pill-based option. Both ...

CHICAGO — Semaglutide, a glucagon-like peptide (GLP-1) receptor agonist, has shown convincing benefits in yet another population: patients with peripheral arterial disease (PAD). In the STRIDE ...

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic ...

The prospect of a pill rather than an injection is obviously appealing to some people, but will fear of needles be enough to ...

New data suggests that the benefits of Novo Nordisk’s GLP-1 agonist semaglutide in preventing cardiovascular diseases may not simply be a result of weight loss. The analysis comes from long-term ...

Novo Nordisk’s SOUL trial confirms that oral semaglutide significantly reduces the risk of heart attack, stroke, and ...

3 Coupled with the metabolic benefits of this drug, the Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) trial showed a 20% reduction in major cardiovascular events ...

Popular medications for obesity and diabetes have been linked to an increased risk of hair loss, particularly for women. Researchers and doctors weigh in.

an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular benefits as the injectable forms of the drug, researchers reported at the American College of Cardiology scientific ...

Uptake of semaglutide remains low due to cost, supply issues, and payer approval challenges, despite its benefits. The SELECT trial demonstrated semaglutide's efficacy in reducing cardiovascular ...

Image: Adobe Stock “The study design ... Data from SOUL are further testament to the benefits of GLP-1s, particularly semaglutide, in patients with CV risk, namely those with diabetes and ...

"Results from STEP UP further strengthen the clinical profile of semaglutide for the treatment of obesity, in addition to the health benefits already established with Wegovy, including ...